Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR142 | Q7Z601 | 3/20 | 0.46 |
| ▸ | BRAF | P15056 | 11/20 | 0.43 |
| ▸ | ABL1 | P00519 | 5/20 | 0.41 |
| ▸ | BCR | P11274 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13436377 | 0.93 | BRAF (0.47) | GPR142BRAFABL1BCRRAF1 | |
| SCHEMBL13436371 | 0.93 | BRAF (0.46) | GPR142BRAFRAF1 | |
| SCHEMBL13436370 | 0.92 | BRAF (0.46) | GPR142BRAFABL1BCRRAF1 | |
| SCHEMBL12465274 | 0.91 | BRAF (0.51) | GPR142BRAFABL1BCR | |
| SCHEMBL13436192 | 0.89 | BRAF (0.47) | BRAFABL1BCRRAF1 | |
| SCHEMBL13436375 | 0.88 | BRAF (0.45) | GPR142BRAFABL1BCR | |
| SCHEMBL2302551 | 0.87 | ABL1 (0.51) | GPR142BRAFABL1BCRKCNH2 | |
| SCHEMBL12398214 | 0.86 | GPR142 (0.56) | GPR142BRAFABL1BCR | |
| SCHEMBL15869562 | 0.86 | GPR142 (0.57) | GPR142BRAFRAF1 | |
| SCHEMBL13436376 | 0.86 | GPR142 (0.46) | GPR142BRAFABL1BCRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350052-B1 | ANTIPROLIFERATIVE COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2014-08-13 | — | — | EP | claimed |
| US-8778929-B2 | Substituted heteroaryl inhibitors of B-RAF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-15 | — | — | US | claimed |
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | claimed |
| CN-102227421-A | Anti-proliferation compounds | BOEHRINGER INGELHEIM INT | 2011-10-26 | — | — | CN | claimed |
| US-8778929-B2 | Substituted heteroaryl inhibitors of B-RAF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-15 | — | — | US | disclosed |
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| WO-2010034838-A2 | NEW CHEMICAL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312939-A1 | NEW CHEMICAL COMPOUNDS | CCNA1, CCNT1, MKI67 | GPR142 3944/4885BRAF 433/4885ABL1 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.